ProCE Banner Activity

(Neo)Adjuvant Therapy in HER2-Negative Early Breast Cancer Treatment Selection Tool

Tool

Learn how 5 experts incorporate the latest evidence on (neo)adjuvant therapy into the management of HER2-negative breast cancer using this Interactive Decision Support Tool.

Released: October 06, 2023

Expiration: October 05, 2024

Share

Faculty

Tanya Gupta

Tanya Gupta, MD

Palo Alto Medical Foundation
Palo Alto, California

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Tiffany A Traina

Tiffany A Traina, MD, FASCO

Associate Attending, Breast Medicine Service
Vice Chair, Department of Medicine
Section Head, TNBC Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
New York, New York

Denise A. Yardley

Denise A. Yardley

Sarah Cannon Research Institute
Senior Investigator, Breast Cancer Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Tanya Gupta, MD

Palo Alto Medical Foundation
Palo Alto, California

Tanya Gupta, MD: consultant/advisor/speaker: AstraZeneca, Biotheranostics, Gilead.

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: 4D Pharma, AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Lilly, Menarini, Merck, Mersana, Myovant, Novartis, Oncosec, Puma, SeaGen, Silicon Biosystems, Takeda; researcher: Ascentage, AstraZeneca, Genetech/Roche, Lilly, Novartis, SeaGen. 

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Pharma, Lilly, G1 Therapeutics, Novartis, Puma; researcher (paid to institution): Genentech, Gilead, Lilly, Merck.

Tiffany A Traina, MD, FASCO

Associate Attending, Breast Medicine Service
Vice Chair, Department of Medicine
Section Head, TNBC Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
New York, New York

Tiffany A. Traina, MD: consultant/advisor: Agendia, AstraZeneca, BioTheranostics, Blueprint Medicines, Daiichi Sankyo, Ellipses Pharma, Fuji Pharma, G1 Therapeutics, GE Healthcare, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Hengrui Pharmaceuticals, Infinity, Iteos Therapeutics, Merck, Novartis, Pfizer, SeaGen, TerSera; researcher (paid to institution): Astellas Pharma, AstraZeneca, Ayala Pharma, Carrick Pharma, Daiichi Sankyo, Genentech/Roche, Immunomedics, Innocrin, Pfizer.